Tempest Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $17.6M
- Price
- $1.10
- % Change (Daily % change from the live per-ticker quote feed.)
- +7.84%
- Volume
- 133.9K
About
Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors. Beyond these clinical assets, Tempest is exploring TREX-1, a pivotal cellular enzyme known for its role in regulating the innate immune response within cancerous growths. Established in 2011, Tempest Therapeutics Inc. is headquartered in South San Francisco, California, having previously operated as a subsidiary of Inception Sciences, Inc.
Quick stats
Shares outstanding16.0M
Computed float7.5M
Float / shares46.8%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001544227
Websitehttps://www.tempesttx.com
AI Summary
AI-generated1/13
standardmixedearnings
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
Tempest reported Q2 2026 net loss of $5.2 million ($0.34 per share) and cash balance deteriorated to $0.8 million from $7.7 million at year-end, though operating cash burn of $10.4 million over six months was partially offset by $3.4 million in recent capital raises.
The company announced positive interim results for TPST-2003 with 100% complete response rate across 15 CAR-T-naïve patients in ongoing Phase 1/2a trials, while executing a strategic partnership with Senlang Biotechnology to advance TPST-4003 with first patient dosing expected in Q4 2026.
Board was strengthened with appointments of Drake Richey and Dr. John Yee as independent directors, and Andrew Fang was named Head of Business Development focused on expanding partnerships in China.
Red flags
- cash balance dropped 90% from $7.7M to $0.8M in six months
- operating cash burn of $10.4M over six months exceeds remaining cash balance
- going concern risk highlighted in forward-looking statements